VPS39 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, IF, E |
---|---|
Primary Accession | Q96JC1 |
Other Accession | AAQ05978, 23339 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 101809 Da |
Application Notes | VPS39 antibody can be used for detection of VPS39 by Western blot at 0.5 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 5 μg/mL. |
Gene ID | 23339 |
---|---|
Target/Specificity | VPS39 antibody was raised against a 18 amino acid synthetic peptide near the carboxy terminus of human VPS39. The immunogen is located within amino acids 710 - 760 of VPS39. |
Reconstitution & Storage | VPS39 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | VPS39 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | VPS39 (HGNC:20593) |
---|---|
Synonyms | KIAA0770, TLP, VAM6 |
Function | Regulator of TGF-beta/activin signaling, inhibiting SMAD3- and activating SMAD2-dependent transcription. Acts by interfering with SMAD3/SMAD4 complex formation, this would lead to inhibition of SMAD3-dependent transcription and relieve SMAD3 inhibition of SMAD2-dependent promoters, thus increasing SMAD2- dependent transcription. Does not affect TGF-beta-induced SMAD2 or SMAD3 phosphorylation, nor SMAD2/SMAD4 complex formation. |
Cellular Location | Cytoplasm. Lysosome membrane; Peripheral membrane protein. Late endosome membrane; Peripheral membrane protein. Note=Colocalizes with TGFBR1 and TGFBR2 in cytoplasmic vesicular structures and most prominently in cortical vesicles. |
Tissue Location | Widely expressed, with highest levels in heart, skeletal muscle, kidney, pancreas, brain, placenta and spleen |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
VPS39 Antibody: VPS39 is the mammalian homolog of the yeast vacuolar protein VAM6, that in mammals, promotes lysosome clustering and fusion in vivo. VPS39 is also thought to modulate the TGF-beta response by coupling the TGF-beta receptor complex to the Smad pathway. Similar to the related protein TRAP1, the VPS39 protein is essential for early embryonic development, with mice lacking VPS39 dying at or before E6.5.
References
Nakamura N, Hirata A, Ohsumi Y, et al. Vam2/Vps41p and Vam6/Vps39p are components of a protein complex on the vacuolar membranes and involved in the vacuolar assembly in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 1997; 272:11344-9.
Caplan S, Hartnell LM, Aguilar RC, et al. Human Vam6p promotes lysosome clustering and fusion in vivo. J. Cell Biol. 2001; 154:109-22.
Felici A, Wurthner JU, Parks WT, et al. TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling. EMBO J. 2003; 22:4465-77.
Messler S, Kropp S, Episkopou V, et al. The TGF-b signaling modulators TRAP1/TGFBRAP1 and VPS39/Vam6/TLP are essential for early embryonic development. Immunobiology 2011; 216:343-50.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.